 
 
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: ABT-414
                                 Compound class: 
                                                            Antibody
                                 
                                    
                                        Comment: Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate (ADC), which targets a unique tumour-specific EGFR epitope in some cancer cells [5]. The antibody portion recognises EGFR in glioblastoma cells with EGFR gene amplification or expressing the truncated Δ2-7 EGFR mutant (aka EGFRvIII) [2-3]. The antibody is linked to the cytotoxic agent, monomethyl auristatin F (MMAF; PubChem CID 56841603) (information derived from  Phillips et al. (2013) [4] and Abbvie's webpage for oncology pipeline compounds and references therein [1].
                                    
                                 | 
| Classification  | |
| Compound class | Antibody | 
| International Nonproprietary Names  | |
| INN number | INN | 
| 10263 | depatuxizumab mafodotin | 
| Synonyms  | 
| ABT-414 | 
| Database Links  | |
| GtoPdb PubChem SID | 249565653 | 
| Search PubMed clinical trials | depatuxizumab mafodotin | 
| Search PubMed titles | depatuxizumab mafodotin | 
| Search PubMed titles/abstracts | depatuxizumab mafodotin |